Inside the Nanyang Biologics SPAC Deal: Valuation and dilution
Nanyang Biologics is an AI-driven drug discovery and biotech company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The setup offers exposure to a preclinical platform at a $1.5 billion headline value, but shareholders should watch redemptions, dilution, and whether the deal closes with enough cash.
Nanyang Biologics is an AI-driven drug discovery and biotech company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The setup offers exposure to a preclinical platform at a $1.5 billion headline value, but shareholders should watch redemptions, dilution, and whether the deal closes with enough cash.
Deal at a Glance
SPAC partner: RF Acquisition Corp II
SPAC ticker (trades now): RFAI
Expected post-merger ticker: NYB
Implied valuation: $1.5B
Expected close: late Q3 to early Q4 2026
Est. first trading date: late Q3 to early Q4 2026
Deal status: Shareholder vote scheduled
Source filing: SEC 425 (2026-08-20)
Company Overview
Nanyang Biologics Pte. Ltd. is a Singapore-based private biotech company focused on AI-driven drug discovery, computational chemistry, natural-product-derived therapeutics, and nutraceuticals. Its materials describe an AI-first platform that combines molecular science, high-performance computing, and natural compound research to identify and develop candidates for oncology and chronic diseases.
The company’s disclosed pipeline includes Vecura™ AI, DTIGN, NB-A002, NB-B101, NB-C201, and NB-C301. The lead candidate, NB-A002, is described as a first-in-class DDR therapeutic targeting ILF2, while the other molecules remain preclinical. That puts NYB in the early-stage bucket: interesting science, but still well before the kind of clinical and commercial proof public-market investors usually want.
Industry-wise, the deal sits in the AI drug discovery and biotech lane, where public investors have been willing to pay for platform stories but often demand visible data, partnerships, and capital efficiency. NYB’s materials also lean on the broader trend toward AI-enabled discovery, natural compounds, and chronic-disease therapeutics.
The SPAC Deal
NYB is merging with RF Acquisition Corp II, which trades today as RFAI. The combined company is expected to list on Nasdaq under the reserved ticker NYB. The headline transaction value disclosed publicly is US$1.5 billion, which is the key valuation marker investors should anchor to because the accessible filing snippets do not provide a cleaner enterprise value bridge.
The SPAC side is not starting from a full trust account. RFAC II reported $53,530,961 in trust as of June 30, 2026, down from the original $115,575,000 after redemptions and extensions. It also had 4,831,265 public shares subject to possible redemption out of 8,343,765 ordinary shares outstanding. That means redemption risk is still central: the final cash that actually makes it into the merged company can shrink further before close.
I did not find a disclosed PIPE in the accessible materials, so the deal appears to rely on trust cash and whatever other transaction funding is in the merger documents. Sponsor economics are meaningful: the sponsor bought 2,875,000 founder shares for $25,000, and the sponsor plus EarlyBirdCapital bought private placement units at $10.00 each. The filing also flags that sponsor, affiliates, and management can still earn a positive return even if public shareholders do not, which is the classic de-SPAC dilution issue.
Status-wise, shareholders approved the deal at the August 19, 2026 extraordinary general meeting. The exact closing date was not clearly disclosed in the accessible snippets, but the setup points to a near-term close after approval. On timing, the most reasonable estimate is late Q3 to early Q4 2026, with the first trading window likely shortly after closing under NYB.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
For NYB, the SPAC route gives it a faster path to the public markets than a traditional IPO and lets it present a long-range growth story around AI drug discovery, platform scalability, and pipeline optionality. The company’s materials also reference projections, which are commonly part of de-SPAC presentations and are not available in the same way in a standard IPO roadshow.
The transaction also gives NYB a public currency for future partnerships and potential capital raises, which matters for a preclinical biotech that is still building out its pipeline. In plain terms: the SPAC route is being used to finance a story that is still early, data-dependent, and capital-intensive.
Financial Highlights
The clearest disclosed operating number is cash: NYB had about $888,657 in cash and cash equivalents as of September 30, 2025. That is a small balance for a biotech platform story, which is why the merger proceeds matter so much.
On profitability, the proxy materials show a net loss of about $(3.56) million for FY2024 and net income of $1.34 million for FY2025. The filing snippets also show a revenue figure of $84,586 for FY2025 in a pro forma table, but the excerpt is not clean enough to treat that as a firm operating benchmark. The company says it has projections in the proxy, but the accessible snippets do not include the forecast table, so those forward numbers should be treated as projections, not current results.
Risk Factors
The biggest de-SPAC risk is cash leakage. RFAC II’s trust has already been reduced materially, and the final redemption level was not clearly disclosed in the snippets I could access. If redemptions stay high, the merged company could come out with less cash than investors expect, which is especially important for a preclinical biotech that needs funding to advance programs.
Dilution is the other major overhang. Founder shares, private placement units, and any future warrant-related dilution can weigh on per-share economics even if the business performs. The filing also makes clear that sponsor and management can still come out ahead even if public holders do not. Beyond the SPAC mechanics, shareholders should watch execution risk, clinical risk, and the fact that NYB is still pre-commercial with limited disclosed revenue and a very small cash base.
Comparable Public Companies
The filing’s valuation work references biotechnology companies focused on oncology drug development and cites an EV/revenue multiple range of 4.05x to 6.07x. That is the cleanest disclosed comp context in the materials, but it is a valuation framework rather than a direct peer list.
For public-market cross-checks, investors often look at AI-enabled drug discovery and biotech names such as Recursion Pharmaceuticals (RXRX), Schrödinger (SDGR), Exscientia (EXAI), and Absci (ABSI). These names have generally traded as high-variance platform stories, with sentiment swinging on pipeline updates, partnerships, and cash runway rather than near-term profits. Because NYB is earlier-stage and more natural-product oriented than some of those peers, the market may apply a discount until it shows more clinical evidence.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
This is a classic early-stage de-SPAC setup: a big headline valuation, a small operating base, and a lot riding on whether the merger closes with enough cash to fund the next phase. The deal is already approved, so the main things shareholders should watch now are final redemption levels, whether any additional financing appears, and how much dilution lands in the post-close cap table.
Why this matters now is simple: NYB is trying to re-rate from private biotech story to public-market platform company before it has commercial proof. If the market buys the AI-drug-discovery narrative and the company can use public capital to advance its pipeline, the setup favors upside optionality. If redemptions are heavy or the cash stack comes in light, the valuation can look stretched fast.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
